vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and Mereo BioPharma Group plc (MREO). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Mereo BioPharma Group plc is a UK-based clinical-stage biopharmaceutical company that develops targeted innovative therapies for rare diseases, oncology, and severe chronic conditions. It operates primarily across European and North American markets, advancing multiple late-stage pipeline candidates to address unmet patient medical needs.
ASBP vs MREO — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-7.0M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | 53.2% |
| EPS (diluted) | $-0.04 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.9K | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 | ||
| Q2 23 | — | $9.0M | ||
| Q1 23 | — | $0 |
| Q3 25 | $-1.9M | $-7.0M | ||
| Q3 24 | — | $-15.0M | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-9.0M | ||
| Q2 23 | — | $-1.8M | ||
| Q1 23 | — | $-12.1M |
| Q3 25 | 45.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | -59015.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | -9.0% | ||
| Q1 23 | — | — |
| Q3 25 | -95337.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | -19.5% | ||
| Q1 23 | — | — |
| Q3 25 | $-0.04 | $-0.01 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $-0.01 | ||
| Q2 23 | — | $0.00 | ||
| Q1 23 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $48.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $46.6M |
| Total Assets | $2.4M | $53.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $48.7M | ||
| Q3 24 | — | $80.5M | ||
| Q2 24 | — | $87.4M | ||
| Q1 24 | — | $48.7M | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | $-11.5M | $46.6M | ||
| Q3 24 | — | $-72.5M | ||
| Q2 24 | — | $78.7M | ||
| Q1 24 | — | $42.8M | ||
| Q2 23 | — | $49.7M | ||
| Q1 23 | — | $44.4M |
| Q3 25 | $2.4M | $53.6M | ||
| Q3 24 | — | $88.7M | ||
| Q2 24 | — | $96.1M | ||
| Q1 24 | — | $55.9M | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-7.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.1M | $-7.3M | ||
| Q3 24 | — | $-7.5M | ||
| Q2 24 | — | $-7.9M | ||
| Q1 24 | — | $-8.0M | ||
| Q2 23 | — | $-7.8M | ||
| Q1 23 | — | $-9.2M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
